

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Hidetsugu TSUBOUCHI et al.)
) Group Art Unit:
Application No.: Not Yet Assigned)
) Examiner:
Filed: April 5, 2006)
)
For: 2,3-DIHYDRO-6-)
)
NITROIMIDAZO (2,1-B))
OXAZOLE COMPOUNDS FOR)
THE TREATMENT OF)
TUBERCULOSIS)

U.S. National Phase of International Application No. PCT/JP2004/016492

MAIL STOP PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), applicants bring to the Examiner's attention the documents listed on attached Form PTO/SB/08 and cited in the international search report. Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the documents listed on attached Form PTO/SB/08 and indicate that they were considered by making an appropriate notation on this form.

This Information Disclosure Statement is being filed with the above-referenced application.

The following are listed on the accompanying PTO/SB/08 and are in a non-English language:

1. International Publication No. WO 2004/035547 A1
2. International Publication No. WO 2004/033463 A1

An English-language abstract of the documents are enclosed.

In lieu of a statement of relevance or the translation of the non-English documents, enclosed is an English-language international search report from the European Patent Office in the PCT international application, from which this national phase U.S. application is derived, citing these documents and setting forth the relevance thereof.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

10/574597

Customer No. 22,852

Attorney Docket No. 01197.0268


APR 9 Rec'd PCT/PTO 05 APR 2006

If there is any fee due in connection with the filing of this Statement, please
charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 5, 2006

By: 
Ernest F. Chapman
Reg. No. 25,961

Enclosures
EFC/FPD/gah

IDS Form PTO/SB/08: Substitute for form 1449A/PTO

APR 05 2006

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	
Filing Date	April 5, 2006
First Named Inventor	Hidetsugu TSUBOUCHI
Art Unit	
Examiner Name	
Attorney Docket Number	01197.0268

Sheet 1 of 1

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
/E.S./		WO-2004/035547 A1	04-29-2004	OTSUKA PHARMACEUTICAL CO., LTD.		Abstract
/E.S./		WO-2004-033463 A1	04-22-2004	OTSUKA PHARMACEUTICAL CO., LTD.		Abstract
/E.S./		WO-97-010562	01-16-1997	PATHOGENESIS CORPORATION		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
/E.S./		NAGARAJAN et al.; "NITROIMIDAZOLES XXI 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-b] OXAZOLES WITH ANTITUBERCULAR ACTIVITY"; Eur. J. Med. Chem., Vol. 24, pages 631-633, (1989)	
/E.S./		STOVER et al.; "A SMALL-MOLECULE NITROIMIDAZOPYRAN DRUG CANDIDATE FOR THE TREATMENT OF TUBERCULOSIS"; Nature, Vol. 405, pages 962-966, (2000)	
/E.S./		SEHGAL et al.; "POTENTIAL RADIOSENSITIZING AGENT. 2. SYNTHESIS AND BIOLOGICAL ACTIVITY OF DERIVATIVES OF DINITROIMIDAZOLE WITH OXIRANES"; J. Med. Chem., Vol. 24, pages 601-604, (1981)	
/E.S./		ASHTAKAR et al.; "IN VITRO AND IN VIVO ACTIVITIES OF THE NITROIMIDAZOLE CGI 17341 AGAINST MYCOBACTERIUM TUBERCULOSIS"; Antimicrobial Agents and Chemotherapy, Vol. 37, No. 2, pages 183-186, (1993)	

Examiner Signature	/Ebenezer Sackey/	Date Considered	03/12/2011
--------------------	-------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.